letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12...5152535455565758596061...100101»
  • ||||||||||  letrozole / Generic mfg.
    Review, Journal:  Long non-coding RNAs: novel players in the pathogenesis of polycystic ovary syndrome. (Pubmed Central) -  Feb 12, 2021   
    We summarized in detail regarding aberrant lncRNAs in different specimens of women with PCOS [i.e., granulosa cells (GCs), cumulus cells (CCs), follicular fluid (FF), peripheral blood] and various PCOS rodent models [i.e., dehydroepiandrosterone (DHEA) and letrozole induced models]...Furthermore, new lncRNA-based classifications might be emerging as potent predictors of a particular phenotype in PCOS. Overall, we proposed new insights for the application of precision medicine approaches to the management of PCOS.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  The effect of intra-ovarian androgen priming on ovarian reserve parameters in Bologna poor responders. (Pubmed Central) -  Feb 9, 2021   
    Long-term intra-ovarian androgen priming in the current set-up had no significant effect on hormone levels, AFC and recruitable follicles after ovarian stimulation in Bologna POR patients undergoing IVF. Further studies are needed to explore other androgen priming protocols and the clinical value of priming regimens in IVF.
  • ||||||||||  Duphaston (dydrogesterone) / Abbott
    Clinical, Journal:  Fetal safety of medications used in treating infertility. (Pubmed Central) -  Feb 5, 2021   
    The fetal safety/risks of clomiphene citrate, aromatase inhibitors, metformin, gonadotropins and progestins are discussed...In most clinical studies of assisted reproduction, the primary endpoint is the success in inducing pregnancy, neglecting to report pregnancy outcome and adverse neonatal event. As an example for this reality, it has been estimated that between 1977 to 2005 around 10 million pregnancies were treated with dydrogesterone (DYD) yet till 2019 only very few studies, with a total sample size of less than 600 were reported with regards to fetal safety.
  • ||||||||||  metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
    Clinical, Review, Journal:  Infertility management in women with polycystic ovary syndrome: a review. (Pubmed Central) -  Feb 4, 2021   
    Combination treatment with metformin is often recommended. More recent alternative and adjunctive treatments have been suggested, like inositol, vitamin D, bariatric surgery and acupuncture, but further research is needed for recommendation.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Trial completion date, Trial primary completion date, Metastases:  AMICA: Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (clinicaltrials.gov) -  Feb 3, 2021   
    P2,  N=150, Recruiting, 
    More recent alternative and adjunctive treatments have been suggested, like inositol, vitamin D, bariatric surgery and acupuncture, but further research is needed for recommendation. Trial completion date: Oct 2019 --> Mar 2022 | Trial primary completion date: Oct 2019 --> Mar 2022
  • ||||||||||  Tecentriq (atezolizumab) / Roche
    Trial completion date, Trial initiation date, Trial primary completion date, IO biomarker, MSi-H Companion diagnostic, PARP Companion diagnostic, PD(L)-1 companion diagnostic:  AFT-50 EndoMAP: A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer (clinicaltrials.gov) -  Feb 3, 2021   
    P1/2,  N=60, Not yet recruiting, 
    Therefore, LIR may offer a novel therapeutic intervention to impede PCOS-induced dementia. Trial completion date: Sep 2024 --> Mar 2025 | Initiation date: Sep 2020 --> Mar 2021 | Trial primary completion date: Sep 2023 --> Mar 2024
  • ||||||||||  Visudyne (verteporfin) / Novartis
    Review, Journal:  Reuse of Molecules for Glioblastoma Therapy. (Pubmed Central) -  Feb 3, 2021   
    The current standard of care for GBM is the Stupp protocol which includes surgical resection, followed by radiotherapy concomitant with the DNA alkylator temozolomide; however, survival under this treatment regimen is an abysmal 12-18 months...Extensive activity is also underway to repurpose and reposition therapeutics for GBM, either alone or in combination with the standard of care. In this review, we present select molecules that target different pathways and are at various stages of clinical translation as case studies to illustrate the rationale for their repurposing-repositioning and potential clinical use.
  • ||||||||||  fulvestrant / Generic mfg.
    [VIRTUAL] Inhibition of Estrogen Signaling Reverses Established Inguinal Hernias (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1817;    
    Successful treatment is accompanied by decreased skeletal muscle fibrosis and reversal of myocyte atrophy. These interventions are promising non-surgical treatment options for patients suffering from severe and recurrent inguinal hernias.
  • ||||||||||  letrozole / Generic mfg.
    [VIRTUAL] Aromatase Inhibitors in Erectile Dysfunction (On-Demand) -  Feb 2, 2021 - Abstract #ENDO2021ENDO_1778;    
    These interventions are promising non-surgical treatment options for patients suffering from severe and recurrent inguinal hernias. ABSTRACT AROMATASE INHIBITORS IN ERECTILE DYSFUNCTION Hyperestrogenism may cause erectile dysfunction(ED) by impeding normal penile development,increasing venous vascular permeability and leakage(via VEGF) and by inhibiting testosterone(T)production.Estrogen excess can impair spermatogenesis and may increase the risk of estrogen-sensitive cancers(viz.breast cancer)[1,2]Weekly and biweekly letrozole(2.5 mg),an aromatase inhibitor,has been reported to normalize serum T in males with obesity related hypogonadism and poor sperm quality,respectively.[3,4]A 40-year old insulin requiring,normotensive,obese(BMI-26.9),diabetic(12 years duration) was evaluated for ED.T was 187 ng/dl and estradiol(E2) was 69 pg/ml(normal-11-44 pg/ml) with normal LH and prolactin levels.There was normalization of T(increased to 487 ng/dl) with 2.5 mg letrozole every 3 weeks.Another patient,55 year old male, insulin requiring,hypertensive,obese(BMI-28.8),diabetic(21 years duration) had normalization of T(401 ng/dl) with baseline low T(224.4 ng/dl) and normal E2(33 pg/ml) with T-E2 ratio of less than 10,with weekly 2.5 mg letrozole.There was one kg weight gain and 0.2 ng/ml increase in PSA in two years.These cases highlight the significance of estimating both T and E2 in the evaluation of ED.Moreover,it also highlights the efficacy and safety of weekly and even every 3-week 2.5 mg letrozole therapy.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  Why is letrozole concentration not associated with arthralgia in patients with breast cancer? (Pubmed Central) -  Feb 2, 2021   
    ABSTRACT AROMATASE INHIBITORS IN ERECTILE DYSFUNCTION Hyperestrogenism may cause erectile dysfunction(ED) by impeding normal penile development,increasing venous vascular permeability and leakage(via VEGF) and by inhibiting testosterone(T)production.Estrogen excess can impair spermatogenesis and may increase the risk of estrogen-sensitive cancers(viz.breast cancer)[1,2]Weekly and biweekly letrozole(2.5 mg),an aromatase inhibitor,has been reported to normalize serum T in males with obesity related hypogonadism and poor sperm quality,respectively.[3,4]A 40-year old insulin requiring,normotensive,obese(BMI-26.9),diabetic(12 years duration) was evaluated for ED.T was 187 ng/dl and estradiol(E2) was 69 pg/ml(normal-11-44 pg/ml) with normal LH and prolactin levels.There was normalization of T(increased to 487 ng/dl) with 2.5 mg letrozole every 3 weeks.Another patient,55 year old male, insulin requiring,hypertensive,obese(BMI-28.8),diabetic(21 years duration) had normalization of T(401 ng/dl) with baseline low T(224.4 ng/dl) and normal E2(33 pg/ml) with T-E2 ratio of less than 10,with weekly 2.5 mg letrozole.There was one kg weight gain and 0.2 ng/ml increase in PSA in two years.These cases highlight the significance of estimating both T and E2 in the evaluation of ED.Moreover,it also highlights the efficacy and safety of weekly and even every 3-week 2.5 mg letrozole therapy. No abstract available
  • ||||||||||  atirmociclib (PF-07220060) / Pfizer
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  C4391001: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors (clinicaltrials.gov) -  Feb 1, 2021   
    P1,  N=52, Recruiting, 
    Our data showed that the consumption of thylakoid and caraway extracts for 8 weeks may have beneficial effects on the biochemical and stereological factors in PCOS-induced rats. Trial completion date: Sep 2024 --> May 2024 | Trial primary completion date: Sep 2024 --> May 2024
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Research and development of a silicone letrozole-releasing device to control reproduction in cattle. (Pubmed Central) -  Jan 29, 2021   
    In conclusion, letrozole was released from a silicone matrix in vitro in a dose-dependent manner, and the 15% LSA devices achieved target effects on ovarian function. Results may be used to manufacture a silicone intravaginal device for delivering aromatase inhibitors in a novel synchronization protocol for cattle.
  • ||||||||||  letrozole / Generic mfg.
    Retrospective data, Journal:  Ovarian hyperstimulation syndrome: a clinical retrospective study on 565 inpatients. (Pubmed Central) -  Jan 27, 2021   
    Totally 12 kinds of ovulation induction protocols (Protocol 1: CC; Protocol 2: Gn; Protocol 3: hCG; Protocol 4: GnRh-a; Protocol 5: CC & Gn; Protocol 6: CC & hCG; Protocol 7: Gn & hCG; Protocol 8: GnRh-a & Gn; Protocol 9: CC & Gn & hCG; Protocol 10: GnRh-a & CC & Gn; Protocol 11: Letrozole & Gn & hCG; Protocol 12:GnRh-a & Letrozole & Gn) were analyzed and the Odds Ratio (OR) of each protocol were calculated...Twelve kinds of ovulation induction protocols were analyzed, OR of different protocols were calculated, what is noteworthy is that patients who used GnRh easily developed more severe OHSS than the patients who received oocytes retrieval. We suggest that we may choose ovulation induction protocols according to the OR table while treating women with high-risk factors.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Effects of letrozole administration on growth and reproductive performance in Markhoz goat bucklings. (Pubmed Central) -  Jan 27, 2021   
    No differences were recorded between the sc and im routes of LTZ administration in the measured parameters. To conclude, we have found that LTZ treatment improves growth and reproductive functions of goat bucklings associated with increased serum LH and GH, elevated T and reduced E2 levels in both serum and testis.
  • ||||||||||  everolimus / Generic mfg.
    Trial primary completion date:  Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) -  Jan 26, 2021   
    P2,  N=3, Active, not recruiting, 
    To conclude, we have found that LTZ treatment improves growth and reproductive functions of goat bucklings associated with increased serum LH and GH, elevated T and reduced E2 levels in both serum and testis. Trial primary completion date: Nov 2020 --> Nov 2021
  • ||||||||||  Arimidex (anastrozole) / AstraZeneca, Remedica
    Clinical, Journal:  Local Recurrence of Breast Cancer Eight Years after Mastectomy-A Case Report (Pubmed Central) -  Jan 22, 2021   
    Local recurrence is a target of the curative treatment and requires a multidisciplinary approach, including surgery, drugs, and radiation therapy. We report a case of local recurrence of breast cancer 8 years after mastectomy.
  • ||||||||||  letrozole / Generic mfg.
    Clinical, Journal:  Necrotizing leukocytoclastic small vessel vasculitis associated with letrozole: A case report. (Pubmed Central) -  Jan 21, 2021   
    Pathogenesis of vasculitis caused by aromatase inhibitors is not fully elucidated, but estrogen depletion and idiosyncratic drug reaction has been proposed. Cutaneous leukocytoclastic small vessel vasculitis (CLSVV) resulting from aromatase inhibitors is relatively rare so it is recommended to consider drug-induced CLSVV in other patients treated with aromatase inhibitors.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Clinical, FDA event, Journal:  FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer. (Pubmed Central) -  Jan 15, 2021   
    To support the safety evaluation in male patients, data from two phase 1 studies with palbociclib and safety information from the global safety database, were also reviewed. This article summarizes FDA decision-making and data supporting the approval of palbociclib for the treatment of male patients with HR-positive, HER2-negative advanced or metastatic breast cancer.